Literature DB >> 15561752

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

Charlotte Lewden1, Dominique Salmon, Philippe Morlat, Sibylle Bévilacqua, Eric Jougla, Fabrice Bonnet, Laurence Héripret, Dominique Costagliola, Thierry May, Geneviève Chêne.   

Abstract

BACKGROUND: In the era of highly active antiretroviral therapy (HAART) mortality has decreased substantially among human immunodeficiency virus (HIV)-infected people with access to HAART, but there are concerns regarding co-morbidities and adverse effects of HAART, which may impair vital prognosis. The Mortality 2000 study examined the causes of death in HIV-infected adults at a national level in France in the year 2000.
METHODS: All French hospital wards known to be involved in the management of HIV infection were asked to notify prospectively the deaths that occurred in 2000 among HIV-infected adults. The causes of death were documented using a standardized questionnaire.
RESULTS: The 185 participating wards notified 964 deaths. The main underlying causes of death were AIDS-related (47%, non-Hodgkin's lymphoma: 23%), viral hepatitis (11%, hepatitis C: 9%, hepatitis B: 2%), cancer not related to AIDS or hepatitis (11%), cardiovascular disease (7%), bacterial infections (6%), suicide (4%), and adverse effect of antiretroviral treatments (1%). Among AIDS-related deaths, HIV infection had been diagnosed recently in 20%. Smoking was recorded in 72% of cancer-related deaths and alcohol consumption in 54% of hepatitis-related deaths. Among non-HIV related deaths between 25 and 64 years, the proportion of infectious diseases (including HCV and HBV-related deaths) was higher in HIV-infected adults than in the general population.
CONCLUSIONS: Improved strategies for detecting HIV infection before AIDS-defining complications occur are needed in the era of HAART. The prevention of non-AIDS related cancers, especially lung cancer, the management of non-Hodgkin's lymphoma, and of viral hepatitis are also important priorities.

Entities:  

Mesh:

Year:  2004        PMID: 15561752     DOI: 10.1093/ije/dyh307

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  114 in total

1.  Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users.

Authors:  Mariah M Marshall; Gregory D Kirk; Neil E Caporaso; Meredith C McCormack; Christian A Merlo; John C Hague; Shruti H Mehta; Eric A Engels
Journal:  Addict Behav       Date:  2010-09-26       Impact factor: 3.913

Review 2.  Role of collagen deposition in lymphatic tissues and immune reconstruction during HIV-1 and SIV infections.

Authors:  Jacob D Estes
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

3.  The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

4.  Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients.

Authors:  Emmanuelle Guitton; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  Eur J Clin Pharmacol       Date:  2006-01-17       Impact factor: 2.953

5.  Cigarette smoking and drug use among a nationally representative sample of HIV-positive individuals.

Authors:  Lauren R Pacek; Paul T Harrell; Silvia S Martins
Journal:  Am J Addict       Date:  2014-07-25

6.  Current cigarette smoking among HIV-positive current and former drug users: associations with individual and social characteristics.

Authors:  Lauren R Pacek; Carl Latkin; Rosa M Crum; Elizabeth A Stuart; Amy R Knowlton
Journal:  AIDS Behav       Date:  2014-07

Review 7.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

8.  Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.

Authors:  S Zhao; D Cheng; E Liu; H Yu; H Yang; X Xue; Y Chu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-17       Impact factor: 3.267

9.  Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study.

Authors:  Basmattee Boodram; Michael W Plankey; Christopher Cox; Phyllis C Tien; Mardge H Cohen; Kathryn Anastos; Roksana Karim; Charles Hyman; Ronald C Hershow
Journal:  AIDS Patient Care STDS       Date:  2009-12       Impact factor: 5.078

10.  Cryptococcus gattii, no longer an accidental pathogen?

Authors:  Deborah J Springer; Sujal Phadke; Blake Billmyre; Joseph Heitman
Journal:  Curr Fungal Infect Rep       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.